PIK3CA mutation status in Japanese lung cancer patients
PIK3CA mutation status in Japanese lung cancer patients
复制标题
DOI：
10.1016/j.lungcan.2006.07.006
复制
发表时间：
2006-11-01
期刊：
影响因子：
5.3
通讯作者：
Fujii, Yoshitaka
中科院分区：
文献类型：
--
作者：
Kawano, Osamu;Sasaki, Hidefumi;Fujii, Yoshitaka
PIK 3CA（磷脂酰肌醇3-激酶催化亚基）基因的体细胞突变已在人类癌症患者中发现。以前的报告表明，大约4%的肺癌。携带PIK 3CA基因突变。然而，PIK 3CA基因突变的临床病理背景尚未在肺癌中研究。我们对日本肺癌患者的PIK 3CA基因进行了基因分型。该研究包括在名古屋市立大学医院手术切除的235例肺癌病例。通过基于真实的实时聚合酶链反应（PCR）的测定分析两个PIK 3CA突变热点（外显子9和外显子20）。通过直接测序证实数据。外显子9的体细胞突变率为3.4%。突变包括三个E542 K（G1624 A），三个E545 K（G1633 A），一个E542 Q（G1624 C）和一个Q546 K（C1636 A）。然而，在外显子20中，在我们的肺癌患者中没有突变。PIK 3CA突变与肺癌的性别（女性与男性，p = 0.4162）、年龄（60岁，p = 0.8027）或吸烟状况（从不吸烟者与吸烟者，p = 0.5666）无关。腺癌中PIK 3CA突变发生率（2/135，1.5%）显著低于鳞状细胞。癌（5/77，6.5%，p = 0.0495）。在8例PIK 3CA突变患者中，3例患者还携带EGFR体细胞突变。PIK 3CA基因突变在肺癌中罕见;在腺癌中更罕见。PIK 3CA突变的进一步功能分析是必要的，以研究它们是否可以成为肺癌治疗的靶点。(C)2006爱思唯尔爱尔兰有限公司保留所有权利。
Somatic mutations of the PIK3CA (phosphatidylinostitol 3-kinase catalytic subunit) gene have been found in human cancer patients. Previous reports suggested that about 4% of lung cancers. harbored PIK3CA gene mutations. However, the clinico-pathological background for PIK3CA gene mutations has not yet been investigated in lung cancer. We have genotyped the PIK3CA gene in Japanese lung cancer patients. The study included 235 lung cancer cases surgically removed in Nagoya City University Hospital. The two PIK3CA mutation hot spots (exon 9 and exon 20) were analyzed by real time polymerase chain reaction (PCR)-based assay. The data were confirmed by direct sequencing. In exon 9, somatic mutation was found in eight patients (3.4%). The mutation included three E542K (G1624A), three E545K (G1633A), one E542Q (G1624C), and one Q546K (C1636A). However, in exon 20, there was no mutation in our lung cancer patients. PIK3CA mutations were not correlated with gender (women versus men, p = 0.4162), age (60, p = 0.8027), or smoking status of the lung cancers (never versus smoker, p = 0.5666). PIK3CA mutation incidence was significantly lower in adenocarcinoma (2/135, 1.5%) than in squamous cell. carcinoma (5/77, 6.5%, p = 0.0495). Among eight patients with a PIK3CA mutation, three patients also harbored an EGFR somatic mutation. PIK3CA gene mutations were rare in lung cancer; rarer in adenocarcinoma. Further functional analyses of the PIK3CA mutations are warranted to study if they could be the target of therapy for the lung cancer. (C) 2006 Elsevier Ireland Ltd. All rights reserved.